6 Einträge gefunden

1. Freedom from disease in psoriasis: a Delphi consensus definition by patients, nurses and physicians

   1. van Ee, I
   2. Deprez, E
   3. Egeberg, A
   4. Augustin, M
   5. Conrad, C
   6. Corazza, V
   7. Donati, L

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
2. Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies

   1. Blauvelt, A
   2. Paul, C
   3. van de Kerkhof, P
   4. Warren, R B
   5. Gottlieb, A B
   6. Langley, R G
   7. Brock, F

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
3. Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE-2 and -3

   1. Warren, R B
   2. Hansen, J B
   3. Reich, K
   4. Paul, C
   5. Puig, L

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
4. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study

   1. Reich, K
   2. Puig, L
   3. Szepietowski, J C
   4. Paul, C
   5. Lacour, J P
   6. Tsianakas, A
   7. Sieder, C

   2020 - Forschungsinformationssystem des UKE
5. A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL)

   1. Seneschal, J
   2. Lacour, J-P
   3. Bewley, A
   4. Faurby, M
   5. Paul, C
   6. Pellacani, G
   7. De Simone, C

   2020 - Forschungsinformationssystem des UKE
6. One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis

   1. Reich, K
   2. Puig, L
   3. Paul, C
   4. Kragballe, K
   5. Luger, T
   6. Lambert, J
   7. Chimenti, S

   2014 - Forschungsinformationssystem des UKE